Abstract
Abnormalities of coagulation have been reported in patients with thyroid dysfunction, although there is no clear information to explain the mechanism behind such irregularities. We are presenting a case of subclinical hypothyroidism that came with coagulation disturbance (hypocoagulation). Her symptoms resolved with leothyroxin in 4 weeks. Further studies are needed to clear the pathogenesis of the coagulation disturbance in such setting. The article also outlines some patents on hypothyroidism and hyperthyroidism.
Keywords: Hemostasis, hypercoagulability hypocoagulability, subclinical thyroid dysfunction, thyroid dysfunction, hypothyroidism, Graves’ disease, vitamin-mineral complexes, levothyroxine, Willebrand factor
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title:Subclinical Hypothyroidism and Homeostatic Disturbances: Case Report and Literature Review
Volume: 6 Issue: 2
Author(s): Parvaneh Ehsanzadeh-Cheemeh, Michelle Thompson and Michal Miller
Affiliation:
Keywords: Hemostasis, hypercoagulability hypocoagulability, subclinical thyroid dysfunction, thyroid dysfunction, hypothyroidism, Graves’ disease, vitamin-mineral complexes, levothyroxine, Willebrand factor
Abstract: Abnormalities of coagulation have been reported in patients with thyroid dysfunction, although there is no clear information to explain the mechanism behind such irregularities. We are presenting a case of subclinical hypothyroidism that came with coagulation disturbance (hypocoagulation). Her symptoms resolved with leothyroxin in 4 weeks. Further studies are needed to clear the pathogenesis of the coagulation disturbance in such setting. The article also outlines some patents on hypothyroidism and hyperthyroidism.
Export Options
About this article
Cite this article as:
Ehsanzadeh-Cheemeh Parvaneh, Thompson Michelle and Miller Michal, Subclinical Hypothyroidism and Homeostatic Disturbances: Case Report and Literature Review, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2012; 6 (2) . https://dx.doi.org/10.2174/187221412800604590
DOI https://dx.doi.org/10.2174/187221412800604590 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1
Current Medicinal Chemistry Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Recent Progress in Phosphoinositide 3-Kinases: Oncogenic Properties and Prognostic and Therapeutic Implications
Current Protein & Peptide Science Olive Oil and Cancer Risk: an Update of Epidemiological Findings through 2010
Current Pharmaceutical Design Liver-Enriched Transcription Factors and Their Role in Regulating UDP Glucuronosyltransferase Gene Expression
Current Drug Metabolism Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Cyclopentenone Prostaglandins as Anti-Inflammatory Agents: A Novel Therapeutic Strategy?
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review
Current Drug Metabolism Molecular Modeling of Sulfonylmorpholinopyrimidines as the Ataxia Telangiectasis Mutated and RAD3-related (ATR) Protein Kinase Inhibitors by Computational Explorations
Letters in Drug Design & Discovery Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry BRAF as a Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Probing Protein Binding Sites by Circular Dichroism Spectroscopy
Current Drug Discovery Technologies Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Clinical Application of Ghrelin
Current Pharmaceutical Design Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets